Skip to content
MarketScale
‹ Back to IndustriesSciences

Fiber Optics Show the Sun in a Whole New Light

While we consistently see the latest in astronomical observations disseminated across numerous news sites, the colossal technological leaps necessary to acquire these images often go unrecognized. While it’s obvious we have come a long way from the early refracting telescopes of a few centuries ago, the capabilities provided by the integration of optical fibers are…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Promoted Content
Share
Fiber Optics Show the Sun in a Whole New Light

Key takeaways

01

While we consistently see the latest in astronomical observations disseminated across numerous news sites, the colossal technological leaps necessary to acquire these images often go unrecognized.

02

While it’s obvious we have come a long way from the early refracting telescopes of a few centuries ago, the capabilities provided by the integration of optical fibers are…

While we consistently see the latest in astronomical observations disseminated across numerous news sites, the colossal technological leaps necessary to acquire these images often go unrecognized. While it’s obvious we have come a long way from the early refracting telescopes of a few centuries ago, the capabilities provided by the integration of optical fibers are incredible, to say the least.

First used for astronomical study in the 1970’s, optical fibers have significantly increased what is possible in spectrography. Scientists are now able to observe multiple objects concurrently using a single spectrograph. These fibers also provide exceedingly high resolution and greater versatility with cables that allow for separation between the observation instruments and telescope.

In fact, thanks to fiber optics, the New Jersey Institute of Technology’s Big Bear Solar Observatory recently made groundbreaking advances in the observation of activity on the sun’s surface. Previously, the observatory’s view was somewhat limited in scope. Now, however, science and research teams can observe simultaneous occurrences like solar flares and coronal mass ejections taking place across a wide field of view. Formerly, these events would have been studied separately, a situation that made it quite difficult to understand the complex dynamics at work.

The NJIT utilizes what is known as a multi-conjugate adaptive optics (MCAO) device to record images. The device takes pictures at three different altitudes to produce a distortion free image. It also allows the observatory to receive images of the entirety of a 20,000-mile-wide sunspot. While it’s taken the team over a decade to perfect the adaptive optics used, the results surely speak for themselves.

Fiberguide is a key supplier for optical fiber products such as IFU’s, 2D array and custom v-groove assemblies.

Fiberguide Industries was selected to build the fiber-optic array for the GHOST (Gemini High-resolution Optical SpecTrograph) in the Gemini South telescope. The array uses cutting-edge construction techniques and Fiberguide’s expertise in building high-quality, high-performance fiber optic subsystems. GHOST will provide two-object plus sky spectroscopy at full wavelength coverage from 363-950nm and resolutions from 50,000 to 75,000.

Each fiber will carry a fraction of the light coming from a stellar object to minimize losses due to atmospheric blurring. Parameters such as fiber optic pointing error and insertion loss are minimized by using proprietary Fiberguide construction techniques and the long history of Fiberguide’s experience building these types of arrays for astronomy, security and data communications. The new instrument will allow for the efficient scanning of the night sky. Click here to learn more about Fiberguide’s line of products.

Read more at fiberguide.com

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512